Shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $11.63.
Several analysts recently commented on the stock. Zacks Investment Research cut shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. BidaskClub cut shares of Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 29th. Finally, Credit Suisse Group assumed coverage on shares of Progenics Pharmaceuticals in a research note on Friday, December 7th. They issued an “outperform” rating and a $6.50 price objective for the company.
Shares of NASDAQ PGNX traded down $0.01 during midday trading on Friday, hitting $4.41. The company had a trading volume of 65,570 shares, compared to its average volume of 1,135,981. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.33. Progenics Pharmaceuticals has a twelve month low of $3.62 and a twelve month high of $9.42. The stock has a market capitalization of $355.91 million, a price-to-earnings ratio of -4.95 and a beta of 2.45.
Institutional investors and hedge funds have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund acquired a new position in Progenics Pharmaceuticals during the fourth quarter worth about $32,000. Quantamental Technologies LLC acquired a new position in Progenics Pharmaceuticals during the fourth quarter worth about $42,000. Advisor Group Inc. raised its position in Progenics Pharmaceuticals by 2,466.1% during the fourth quarter. Advisor Group Inc. now owns 12,651 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 12,158 shares during the last quarter. Amalgamated Bank acquired a new position in Progenics Pharmaceuticals during the fourth quarter worth about $53,000. Finally, Boston Advisors LLC acquired a new position in Progenics Pharmaceuticals during the fourth quarter worth about $55,000. Institutional investors own 87.59% of the company’s stock.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Read More: Sell-Side Analysts
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.